/PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from the Phase 3 PAPILLON study evaluating…
/PRNewswire/ — Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and PathAI, a global provider of artificial intelligence-powered…
/PRNewswire/ — With every successive year, the lines between medical devices and consumer electronics become increasingly blurred – medtech companies seek to…
/PRNewswire/ — Invitae (OTC:NVTA), a leading medical genetics company, announced that Labcorp (NYSE: LH), a global leader of innovative and comprehensive…
Following the approval of the first antibody-drug conjugates (ADCs) in the early 2000s, development has increased dramatically, with 14 ADCs now approved and >100 in…
− Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ®; 15…
Following the approval of the first antibody-drug conjugates (ADCs) in the early 2000s, development has increased dramatically, with 14 ADCs now approved and >100 in…
/PRNewswire/ — With every successive year, the lines between medical devices and consumer electronics become increasingly blurred – medtech companies seek to…
/PRNewswire/ — VieCure, a cancer care company, today announced that it is integrating e-prescribing and medication management solutions from health technology…
/PRNewswire/ – 16 Bit Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted a De Novo marketing authorization for Rho™, an…
− Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ®; 15…
